SPHINGOSYLPHOSPHORYLCHOLINE (cas 1670-26-4) protects cardiomyocytes against ischemic apoptosis via lipid raft/PTEN/Akt1/mTOR mediated autophagy

Add time:09/25/2019    Source:sciencedirect.com

Autophagy, evoked by diverse stresses including myocardial ischemia/reperfusion (I/R), profoundly affects the development of heart failure. However, the specific molecular basis of autophagy remains to be elucidated. Here we report that SPHINGOSYLPHOSPHORYLCHOLINE (cas 1670-26-4) (SPC), a bioactive sphingolipid, significantly suppressed apoptosis and induced autophagy in cardiomyocytes. Blocking this SPC evoked autophagy by 3-methyladenine (3MA)-sensitized cardiomyocytes to serum deprivation-induced apoptosis. Subsequent studies revealed that SPC downregulated the phosphorylation of p70S6K and 4EBP1 (two substrates of mTOR) but enhanced that of JNK when inducing autophagy. We identified SPC as a switch for the activity of Akt1, a supposed upstream modulator of both mTOR and JNK. Furthermore, β-cyclodextrin, which destroys membrane cholesterol, abolished the SPC-reduced phosphorylation of both Akt and PTEN, thus inhibiting SPC-induced autophagy. In conclusion, SPC is a novel molecule protecting cardiomyocytes against apoptosis by promoting autophagy. The lipid raft/PTEN/Akt1/mTOR signal pathway is the underlying mechanism and might provide novel targets for cardiac failure therapy.

We also recommend Trading Suppliers and Manufacturers of SPHINGOSYLPHOSPHORYLCHOLINE (cas 1670-26-4). Pls Click Website Link as below: cas 1670-26-4 suppliers

Prev:SPHINGOSYLPHOSPHORYLCHOLINE (cas 1670-26-4) regulates the Hippo signaling pathway in a dual manner
Next:ReviewThe multi-functional role of SPHINGOSYLPHOSPHORYLCHOLINE (cas 1670-26-4))